Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020” report has been added to ResearchAndMarkets.com’s offering.

This quarterly review describes the pipeline of drugs under development for Hereditary Angioedema, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Hereditary Angioedema Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Hereditary Angioedema disease overview, Hereditary Angioedema types, Hereditary Angioedema symptoms, causes, and FDA/EMA approved treatment options.

Hereditary Angioedema Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hereditary Angioedema indication. The report presents near-term and long-term pipeline development trends and potential insights.

Hereditary Angioedema Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 18 companies. Business profiles and contact details of the companies actively perusing Hereditary Angioedema pipeline are assessed.

Hereditary Angioedema R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Hereditary Angioedema discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

(Read more…)

Small Hereditary Angioedema companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Hereditary Angioedema pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Hereditary Angioedema Pipeline Market News and Developments during 2020

The Hereditary Angioedema industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Hereditary Angioedema Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Scope and Coverage

  • Hereditary Angioedema pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
  • Company-company partnerships, company-institute partnerships, and investment details of companies are included
  • Potential licensing/new business opportunities in Hereditary Angioedema pipeline market
  • Disease overview, Pipeline trends, market analysis, and other developments

Companies Profiled

  • Adverum Biotechnologies Inc
  • Attune Pharmaceuticals
  • BioCryst Pharmaceuticals Inc
  • BioMarin Pharmaceutical Inc
  • Cevec Pharmaceuticals GmbH
  • CSL Ltd
  • Generium Pharmaceuticals
  • iBio Inc
  • Intellia Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Kalvista Pharmaceuticals Inc
  • Octapharma AG
  • Pharming Group NV
  • Pharvaris BV
  • RegenxBio Inc
  • Serpinx BV
  • Takeda Pharmaceutical Co Ltd (Shire Plc)
  • Verseon Corp

For more information about this report visit https://www.researchandmarkets.com/r/m0g8bh.



Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.